The director of the Multiple Sclerosis and Neuromyelitis Optica Unit at Massachusetts General Hospital commented on presentations given at the recent event, as well as key takeaways from his own discussion on novel imaging approaches in multiple sclerosis. [WATCH TIME: 2 minutes]
WATCH TIME: 2 minutes
“I think the key takeaway is that we're continually improving our ability to both diagnose and monitor people with multiple sclerosis, and ultimately, these types of improvements will enhance our ability to understand the pathophysiology of MS.”
At NeurologyLive®’s Institutional Perspectives in Neurology meeting on Feb 9, 2022, experts in the field of multiple sclerosis (MS) presented on a variety of topics, including B-cell depleting medications recently approved by the FDA for MS, as well as medications recently approved for neuromyelitis optica spectrum disorder (NMOSD). Eric Klawiter, MD, MSc, associate neurologist, and director, Multiple Sclerosis and Neuromyelitis Optica Unit, Massachusetts General Hospital; and associate professor of neurology, Harvard Medical School, gave a talk on neuroimaging in MS and the potential new approaches have for this patient population.
In conversation with NeurologyLive®, Klawiter highlighted key points from other presentations, citing his interest in the recently FDA-approved treatments and looking at implications for patients who switch from oneB-cell depleting agent to another. Having treatments that are approved by the FDA for patients with NMOSD is another notable advance, he said, with presentations shedding light on progress that has been made in that sector.